Cargando…

Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors

BACKGROUND: Outcome of consecutive patients with locally advanced non-small cell lung cancer and histopathologically proven mediastional lymph node metastases treated with induction chemotherapy, neoadjuvant radiochemotherapy and thoracotomy at the West German Cancer Center between 08/2000 and 06/20...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pöttgen, Christoph, Stuschke, Martin, Graupner, Britta, Theegarten, Dirk, Gauler, Thomas, Jendrossek, Verena, Freitag, Lutz, Jawad, Jehad Abu, Gkika, Eleni, Wohlschlaeger, Jeremias, Welter, Stefan, Hoiczyk, Matthias, Schuler, Martin, Stamatis, Georgios, Eberhardt, Wilfried
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428235/ https://www.ncbi.nlm.nih.gov/pubmed/25943191 http://dx.doi.org/10.1186/s12885-015-1389-4

Ejemplares similares

Long-term survival of patients with central or > 7 cm T4 N0/1 M0 non-small-cell lung cancer treated with definitive concurrent radiochemotherapy in comparison to trimodality treatment
por: Guberina, Nika, et al.
Publicado: (2022)

Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence
por: Pöttgen, Christoph, et al.
Publicado: (2017)

Impact of EBUS-TBNA in addition to [(18)F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC
por: Guberina, Maja, et al.
Publicado: (2021)

Prognostic Value of Postinduction Chemotherapy Volumetric PET/CT Parameters for Stage IIIA or IIIB Non–Small Cell Lung Cancer Patients Receiving Definitive Chemoradiotherapy
por: Guberina, Maja, et al.
Publicado: (2021)

βV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer
por: Christoph, D C, et al.
Publicado: (2012)

Patterns of nodal spread in stage III NSCLC: importance of EBUS-TBNA and (18)F-FDG PET/CT for radiotherapy target volume definition
por: Guberina, Maja, et al.
Publicado: (2021)

N-staging in large cell neuroendocrine carcinoma of the lung: diagnostic value of [(18)F]FDG PET/CT compared to the histopathology reference standard
por: Hautzel, Hubertus, et al.
Publicado: (2021)

Prediction of malignant lymph nodes in NSCLC by machine-learning classifiers using EBUS-TBNA and PET/CT
por: Guberina, Maja, et al.
Publicado: (2022)

Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial
por: Pöttgen, C., et al.
Publicado: (2021)

ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy
por: Guberina, Maja, et al.
Publicado: (2020)

Correction: ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy
por: Guberina, Maja, et al.
Publicado: (2020)

Diagnostic approach to interstitial pneumonias in a single centre: report on 88 cases
por: Theegarten, Dirk, et al.
Publicado: (2012)

Re-irradiation of recurrent head and neck carcinomas: comparison of robust intensity modulated proton therapy treatment plans with helical tomotherapy
por: Stuschke, Martin, et al.
Publicado: (2013)

Multi-scenario based robust intensity-modulated proton therapy (IMPT) plans can account for set-up errors more effectively in terms of normal tissue sparing than planning target volume (PTV) based intensity-modulated photon plans in the head and neck region
por: Stuschke, Martin, et al.
Publicado: (2013)

Spatial and dosimetric evaluation of residual distortions of prostate and seminal vesicle bed after image‐guided definitive and postoperative radiotherapy of prostate cancer with endorectal balloon
por: Levegrün, Sabine, et al.
Publicado: (2020)

Pulmonary manifestation of a condition resembling Kasabach–Merritt syndrome in a woman with abdominal angiomatosis associated with consumptive coagulopathy – surgical management: a case report
por: Cheufou, Danjouma Housmanou, et al.
Publicado: (2015)

SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy
por: De-Colle, Chiara, et al.
Publicado: (2017)

Potential Prognostic Value of Preoperative Leukocyte Count, Lactate Dehydrogenase and C-Reactive Protein in Thymic Epithelial Tumors
por: Valdivia, Daniel, et al.
Publicado: (2021)

Radiochemotherapy
Publicado: (1998)

Combined Radiochemotherapy: Metalloproteinases Revisited
por: Waller, Verena, et al.
Publicado: (2021)

Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age
por: HOICZYK, MATHIAS, et al.
Publicado: (2013)

Respiration-controlled radiotherapy in lung cancer: Systematic evaluation of the optimal application practice
por: Guberina, M., et al.
Publicado: (2023)

Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the Adrisk trial
por: Wiegand, Susanne, et al.
Publicado: (2023)

Fractionation versus Adaptation for Compensation of Target Volume Changes during Online Adaptive Radiotherapy for Bladder Cancer: Answers from a Prospective Registry
por: Pöttgen, Christoph, et al.
Publicado: (2023)

Predictive Factors of the Response of Rectal Cancer to Neoadjuvant Radiochemotherapy
por: Spolverato, Gaya, et al.
Publicado: (2011)

Morphological and Molecular Changes of the Myocardium After Left Ventricular Mechanical Support
por: Baba, Hideo A, et al.
Publicado: (2008)

Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis
por: Walter, Robert Fred Henry, et al.
Publicado: (2015)

Intensified neoadjuvant radiochemotherapy for rectal cancer enhances surgical complications
por: Schiffmann, Leif, et al.
Publicado: (2013)

Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab
por: Pogorzelski, Michael, et al.
Publicado: (2021)

Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma
por: Lewitzki, Victor, et al.
Publicado: (2019)

Lung Cancer Surgery after Neoadjuvant Immunotherapy
por: Stefani, Dirk, et al.
Publicado: (2021)

Identification of potential metabolic biomarkers of rectal cancer and of the effect of neoadjuvant radiochemotherapy
por: Rodríguez-Tomàs, Elisabet, et al.
Publicado: (2021)

RADIANCE – Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial
por: Martin, Daniel, et al.
Publicado: (2020)

The effects of motion on the dose distribution of proton radiotherapy for prostate cancer
por: Qamhiyeh, Sima, et al.
Publicado: (2012)

Concurrent radiochemotherapy in advanced hypopharyngeal cancer
por: Krstevska, Valentina, et al.
Publicado: (2010)

Capecitabine in adjuvant radiochemotherapy for gastric adenocarcinoma
por: Oblak, Irena, et al.
Publicado: (2014)

Ösophaguskarzinom: Prognoseverbesserung durch neoadjuvante Radiochemotherapie
por: Knippen, Stefan, et al.
Publicado: (2021)

Prognostic value of the micronucleus assay for clinical endpoints in neoadjuvant radiochemotherapy for rectal cancer
por: Dröge, Leif Hendrik, et al.
Publicado: (2021)

The role of neoadjuvant radiochemotherapy in the management of localized high-grade soft tissue sarcoma
por: Kobus, Marta, et al.
Publicado: (2022)

Neoadjuvant versus definitive radiochemotherapy of locoregionally advanced oesophageal cancer—who benefits?
por: Schiffner, Christoph, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3lnhpa59gqq5ub16nenb2udohj